Cargando…
Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19)
COVID-19 patients (n = 34) suffering from ARDS were treated with tocilizumab (TCZ). Outcome was classified in two groups: “Death” and “Recovery”. Predictive factors of mortality were studied. Mean age was 75.3, mean oxygen (O(2)) requirements 10.4 l/min. At baseline, all patients had multiple biolog...
Autores principales: | Lohse, Anne, Klopfenstein, Timothée, Balblanc, Jean-Charles, Royer, Pierre-Yves, Bossert, Marie, Gendrin, Vincent, Charpentier, Aline, Bozgan, Ana-Maria, Badie, Julio, Bourgoin, Charlotte, Contreras, Remy, Mazurier, Isabelle, Conrozier, Thierry, Zayet, Souheil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Institut Pasteur. Published by Elsevier Masson SAS.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305501/ https://www.ncbi.nlm.nih.gov/pubmed/32574789 http://dx.doi.org/10.1016/j.micinf.2020.06.005 |
Ejemplares similares
-
Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
por: Klopfenstein, T., et al.
Publicado: (2020) -
Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients
por: Klopfenstein, Timothée, et al.
Publicado: (2020) -
Systematic Review and Subgroup Meta-analysis of Randomized Trials to Determine Tocilizumab’s Place in COVID-19 Pneumonia
por: Klopfenstein, Timothée, et al.
Publicado: (2021) -
Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?
por: Klopfenstein, Timothée, et al.
Publicado: (2021) -
Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM
por: Klopfenstein, Timothée, et al.
Publicado: (2022)